Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan Alone or Combined With Standard of Care Therapies for Prostate Cancer
NCT06168487Phase 1Recruiting
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of telmisartan in prostate cancer (PCa) (2 cohorts). Primary endpoint: Tolerability of oral telmisartan at 12 months. Started Apr 2024; status: recruiting.
02
Drugs
telmisartan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06168487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168487.